Disclosed herein are concentrated therapeutic phospholipid compositions； methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and dieases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition. In one embodiment the composition comprises docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) and astaxanthin wherein the total phospholipids in the composition are at a concentration between 60% to 99% (w/w).
